Foresite Capital Management III’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Foresite Capital Management III’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-45,273	Closed	-$5.29M	–	28
2017 Q2	$5.29M	Sell	45,273 -46,527	-51%	-$5.78M	1.73%	13
2017 Q1	$11.3M	Buy	+91,800	New	+$12M	4.35%	7
2016 Q3	–	Sell	-20,599	Closed	-$2.67M	–	19
2016 Q2	$2.67M	Hold	20,599	–	–	1.83%	12
2016 Q1	$1.93M	Buy	+20,599	New	+$2.24M	1.49%	17

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Foresite Capital Management III's BLCM Position: Q3 2017 in Review

Foresite Capital Management III sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2017, closing a stake of 45,273 shares — an estimated $5.29M sold.

Foresite Capital Management III first reported a position in BLCM in Q1 2016 and held it in 4 quarters. The position peaked at $11.3M in Q1 2017. 88 funds tracked by Wall St. Rank hold BLCM as of Q3 2017.

Foresite Capital Management III reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Foresite Capital Management III sold 45,273 Bellicum Pharmaceuticals, Inc. shares in Q3 2017, an estimated $5.29M.
Foresite Capital Management III first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2016 and held it in 4 quarters.
Foresite Capital Management III's Bellicum Pharmaceuticals, Inc. position peaked at $11.3M in Q1 2017.
88 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2017.

Based on Foresite Capital Management III's 13F filing for Q3 2017, filed 13 Nov 2017.